The withdrawal of torcetrapib from drug development: implications for the future of drugs that alter HDL metabolism

Bibliography

• MCKENNEY JM, DAVIDSON MH, SHEAR CL, REVKIN JH: Efficacy and safety of torcetrapib, a novel cholesteryl ester transfer protein inhibitor, in individuals with below-average high-density lipoprotein cholesterol levels on a background of atorvastatin. J. Am. Coll. Cardiol. (2006) 48(9):1782-1790.
   PubMed Web of Science ®Google Scholar
• FRANCESCHINI G: Epidemiologic evidence for high-density lipoprotein cholesterol as a risk factor for coronary artery disease. Am. J. Cardiol. (2001) 88(12A):N9-N13.
   PubMed Web of Science ®Google Scholar
• JOHANSEN O, ABDELNOOR M, BREKKE M, SELJEFLOT I, HOSTMARK AT, ARNESEN H: Predictors of restenosis after coronary angioplasty. A study on demographic and metabolic variables. Scand. Cardiovasc. J. (2001) 35(2):86-91.
   PubMed Web of Science ®Google Scholar
• ROBINS SJ, COLLINS D, WITTES JT et al.; VA-HIT STUDY GROUP; VETERANS AFFAIRS HIGH-DENSITY LIPOPROTEIN INTERVENTION TRIAL: Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial. JAMA (2001) 285(12):1585-1591.
   PubMed Web of Science ®Google Scholar
• BROWN BG, ZHAO XQ, CHAIT A et al.: Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N. Engl. J. Med. (2001) 345(22):1583-1592.
   PubMed Web of Science ®Google Scholar
• TARDIF JC, GREGOIRE J, L'ALLIER PL et al.; EFFECT OF RHDL ON ATHEROSCLEROSIS-SAFETY AND EFFICACY (ERASE) INVESTIGATORS: Effects of reconstituted high-density lipoprotein infusions on coronary atherosclerosis: a randomized controlled trial. JAMA (2007) 297(15):1675-1682.
   PubMed Web of Science ®Google Scholar
• MCKENNEY JM, DAVIDSON MH, SHEAR CL, REVKIN JH: Efficacy and safety of torcetrapib, a novel cholesteryl ester transfer protein inhibitor, in individuals with below-average high-density lipoprotein cholesterol levels on a background of atorvastatin. J. Am. Coll. Cardiol. (2006) 48(9):1782-1790.
   PubMed Web of Science ®Google Scholar
• DAVIDSON MH, MCKENNEY JM, SHEAR CL, REVKIN JH: Efficacy and safety of torcetrapib, a novel cholesteryl ester transfer protein inhibitor, in individuals with below-average high-density lipoprotein cholesterol levels. J. Am. Coll. Cardiol. (2006) 48(9):1774-1781.
   PubMed Web of Science ®Google Scholar
• KOBAYASHI J, OKAMOTO H, OTABE M, BUJO H, SAITO Y: Effect of HDL, from Japanese white rabbit administered a new cholesteryl ester transfer protein inhibitor JTT-705, on cholesteryl ester accumulation induced by acetylated low density lipoprotein in J774 macrophage. Atherosclerosis (2002) 162(1):131-135.
   PubMed Web of Science ®Google Scholar
• DE GROOTH GJ, KUIVENHOVEN JA, STALENHOEF AF et al.: Efficacy and safety of a novel cholesteryl ester transfer protein inhibitor, JTT-705, in humans: a randomized phase II dose-response study Circulation (2002) 105(18):2159-2165.
   PubMed Web of Science ®Google Scholar
• KUIVENHOVEN JA, DE GROOTH GJ, KAWAMURA H et al.: Effectiveness of inhibition of cholesteryl ester transfer protein by JTT-705 in combination with pravastatin in type II dyslipidemia. AM. J. Cardiol. (2005) 95(9):1085-1088.
   PubMed Web of Science ®Google Scholar
• KASTELEIN JJ, VAN LEUVEN SI, BURGESS L et al.; RADIANCE 1 INVESTIGATORS: Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia. N. Engl. J. Med. (2007) 356(16):1620-1630.
   PubMed Web of Science ®Google Scholar
• BOTS ML, VISSEREN FL, EVANS GW et al.; RADIANCE 2 INVESTIGATORS: Torcetrapib and carotid intima-media thickness in mixed dyslipidaemia (RADIANCE 2 study): a randomised, double-blind trial. Lancet (2007) 370(9582):153-160.
   PubMed Web of Science ®Google Scholar
• NISSEN SE, TARDIF JC, NICHOLLS SJ et al.; ILLUSTRATE INVESTIGATORS: Effect of torcetrapib on the progression of coronary atherosclerosis. N. Engl. J. Med. (2007) 356(13):1304-1316.
   PubMed Web of Science ®Google Scholar
• HANSSON L, ZANCHETTI A, CARRUTHERS SG et al.: Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet (1998) 351(9118):1755-1762.
   PubMed Web of Science ®Google Scholar
• DAHLOF B, SEVER PS, POULTER NR et al.; ASCOT INVESTIGATORS: Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian cardiac outcomes trial-blood pressure lowering arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet (2005) 366(9489):895-906.
   PubMed Web of Science ®Google Scholar
• JULIUS S, KJELDSEN SE, WEBER M et al.; VALUE TRIAL GROUP: Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet (2004) 363(9426):2022-2031.
   PubMed Web of Science ®Google Scholar
• NISSEN SE, TUZCU EM, LIBBY P et al.; CAMELOT INVESTIGATORS: Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial. JAMA (2004) 292(18):2217-2225.
   PubMed Web of Science ®Google Scholar
• TERPSTRA WF, MAY JF, SMIT AJ, GRAEFF PA, MEYBOOM-DE JONG B, CRIJNS HJ: Effects of amlodipine and lisinopril on intima-media thickness in previously untreated, elderly hypertensive patients (the ELVERA trial). J. Hypertens. (2004) 22(7):1309-1316.
   PubMed Web of Science ®Google Scholar
• MILIONIS HJ, LIBEROPOULOS E, GOUDEVENOS J, BAIRAKTARI ET, SEFERIADIS K, ELISAF MS: Risk factors for first-ever acute ischemic non-embolic stroke in elderly individuals. Int. J. Cardiol. (2005) 99(2):269-275.
   PubMed Web of Science ®Google Scholar
• KRIMBOU L, MARCIL M, GENEST J: New insights into the biogenesis of human high-density lipoproteins. Curr. Opin. Lipidol. (2006) 17(3):258-267.
   PubMed Web of Science ®Google Scholar
• MINEO C, DEGUCHI H, GRIFFIN JH, SHAUL PW: Endothelial and antithrombotic actions of HDL. Circ. Res. (2006) 98(11):1352-1364.
   PubMed Web of Science ®Google Scholar
• SCHAEFER EJ, ASZTALOS BF: Where are we with high-density lipoprotein raising and inhibition of cholesteryl ester transfer for heart disease risk reduction? Curr. Opin. Cardiol. (2007) 22(4):373-378.
   PubMed Web of Science ®Google Scholar
• CLARK RW, RUGGERI RB, CUNNINGHAM D, BAMBERGER MJ: Description of the torcetrapib series of cholesteryl ester transfer protein inhibitors, including mechanism of action. J. Lipid Res. (2006) 47(3):537-552.
   PubMed Web of Science ®Google Scholar
• MOREHOUSE LA, SUGARMAN ED, BOURASSA PA et al.: Inhibition of CETP activity by torcetrapib reduces susceptibility to diet-induced atherosclerosis in New Zealand white rabbits. J. Lipid Res. (2007) 48(6):1263-1272.
   PubMed Web of Science ®Google Scholar
• VAN DER WESTHUYZEN DR, DE BEER FC, WEBB NR: HDL cholesterol transport during inflammation. Curr. Opin. Lipidol. (2007) 18(2):147-151.
   PubMed Web of Science ®Google Scholar